The Royal Marsden, together with its academic partner, The Institute of Cancer Research, is designated as the UK’s only specialist Biomedical Research Centre for cancer.
The Royal Marsden and The Institute of Cancer Research continue to develop new technologies and therapies based on the latest breakthroughs in basic and applied science.
The BRIM-3 trial results represent a dramatic advance in the treatment of metastatic melanoma. A personalised therapy called vemurafenib targets the faulty BRAF protein and was seen to both prolong the period of disease control and increase life expectancy.
This classic example of bench to bedside translational research that has yielded a personalised treatment with a completely new class of anti-cancer treatment.
The Royal Marsden led international research into improved treatments for women with a particular subtype of breast cancer.
Making personalised treatment a clinical reality is a challenge that is being pioneered in this landmark breast cancer trial.
The PARSPORT trial tested intensity modulated radiotherapy (IMRT) on people with head and neck cancer.
Research into this drug received worldwide acclaim when results from the Phase I clinical trial were published.
This technology could help personalise cancer treatments and provide a convenient test to monitor response to drug treatment in the clinic.
The results from two European clinical trials have paved the way to individualising treatment for children with neuroblastoma.
The Royal Marsden has been a major contributing centre to national trials in both prostate and breast cancer, assessing new radiotherapy techniques and drugs.